Normal Values of Oxidative Stress, Taurine, and Related Markers

Sponsor
University of Colorado, Denver (Other)
Overall Status
Completed
CT.gov ID
NCT02649777
Collaborator
(none)
22
1
23
1

Study Details

Study Description

Brief Summary

The role of oxidative stress in disease pathology is increasingly recognized. At present, the development of biomarkers of this state is in its infancy and the availability of clinically validated assays is lacking. This study will better determine normal values for specific biomarkers of oxidative stress. It will also investigate normal values of taurine, a natural occurring oxidative stress protectant. A primary and specific application of this data is for the evaluation of oxidative stress, levels of the natural protectant taurine, and of associated inflammation in the context of cystathionine β-synthase (ClinicalTrials.gov study: Oxidative Stress Markers in Inherited Homocystinuria and the Impact of Taurine).

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This study is a one-time collection of blood and urine samples in healthy individuals. Subjects have to be fasting for 3 hours prior to the blood sampling. A maximum of 7.5 mLs of blood (1 and 1/5 teaspoon) and a urine sample will be collected.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    22 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Normal Values of Oxidative Stress, Taurine, and Related Markers
    Study Start Date :
    Jan 1, 2016
    Actual Primary Completion Date :
    Jun 1, 2016
    Actual Study Completion Date :
    Dec 1, 2017

    Outcome Measures

    Primary Outcome Measures

    1. Oxidative stress marker: TBARS [Time 0]

      Single Draw for one-time analysis

    2. Metabolite antioxidant: Taurine [Time 0]

      Single Draw for one-time analysis

    Secondary Outcome Measures

    1. Inflammation marker: Supper oxide dismutase (SOD) [Time 0]

      Single Draw for one-time analysis

    2. Inflammation marker: TGFβ [Time 0]

      Single Draw for one-time analysis

    3. Inflammation marker: myeloperoxidase [time 0]

      Single Draw for one-time analysis

    4. Metabolites: S-adenosylmethionine and S-adenosylhomocysteine [Time 0]

      Single Draw for one-time analysis (same units)

    5. Vascular function: Thromboxane B2 metabolites [Time 0]

      Single Draw for one-time analysis (same units)

    6. Oxidative stress: dityrosine [Time 0]

      Single Draw for one-time analysis

    7. Inflammation markers: IL1α, IL-1β, IL10, TNFα [Time 0]

      Single Draw for one-time analysis; ELISA assay (same units)

    8. Inflammation markers: cytokines: IL1α, IL-1β IL-1ra, IL6, IL8, IL17, MCP-1,MIP-1, MIP1α, MIPβ [Time 0]

      Single Draw for one-time analysis; Luminex assay (same units)

    9. Inflammation markers: cytokines: TNFα, IL4, IL10 and IL12 [Time 0]

      Single Draw for one-time analysis; high sensitivity Luminex assay (same units)

    10. Inflammation marker: high sensitivity CRP [Time 0]

      Single Draw for one-time analysis

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    8 Years to 50 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Age: Over 8 years old and less than 50 years
    Exclusion Criteria:
    • Pregnancy: Females who are pregnant or lactating will be excluded from the study as the influence of pregnancy on the markers is not known nor is the impact of pregnancy on taurine known.

    • Antioxidant use: Individuals taking taurine, over the counter energy drinks containing taurine or other high dose antioxidants such as Vitamin C or E, coenzyme Q, carotenes, selenium will be excluded as such intake will likely impact laboratory results.

    • Inflammatory status:

    • Individuals who have a significant chronic illness or state that has a known or suspected marked inflammatory component or oxidative stress component will be excluded from the study as the illness will impact inflammatory markers.

    • Patients with an acute illness, which may impact inflammatory biomarkers, will be postponed for study entry until the acute illness is resolved. Entry into the study at a later day will be offered. The study visit will not be conducted within 3 weeks of the acute illness.

    • Smoking within the past 12 months will be excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Children's Hospital Colorado Aurora Colorado United States 80045

    Sponsors and Collaborators

    • University of Colorado, Denver

    Investigators

    • Principal Investigator: Johan LK Van Hove, MD, PhD, MBA, University of Colorado, Denver

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University of Colorado, Denver
    ClinicalTrials.gov Identifier:
    NCT02649777
    Other Study ID Numbers:
    • 15-2091
    • UL1TR001082
    First Posted:
    Jan 7, 2016
    Last Update Posted:
    Jan 19, 2018
    Last Verified:
    Jan 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Keywords provided by University of Colorado, Denver

    Study Results

    No Results Posted as of Jan 19, 2018